vs
Side-by-side financial comparison of Jazz Pharmaceuticals plc (JAZZ) and SouthState Bank Corp (SSB). Click either name above to swap in a different company.
Jazz Pharmaceuticals plc is the larger business by last-quarter revenue ($1.2B vs $661.7M, roughly 1.8× SouthState Bank Corp). SouthState Bank Corp runs the higher net margin — 34.1% vs 17.0%, a 17.1% gap on every dollar of revenue. Over the past eight quarters, SouthState Bank Corp's revenue compounded faster (37.4% CAGR vs 15.2%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
SouthState Bank, based in Winter Haven, Florida, is an American bank and a subsidiary of SouthState Corporation, a bank holding company. As of May 26, 2025, the company had 371 branches in South Carolina, North Carolina, Georgia, Florida, Alabama, Virginia, Colorado and Texas.
JAZZ vs SSB — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.2B | $661.7M |
| Net Profit | $203.5M | $225.8M |
| Gross Margin | — | — |
| Operating Margin | 21.2% | 15.1% |
| Net Margin | 17.0% | 34.1% |
| Revenue YoY | 10.1% | — |
| Net Profit YoY | 6.5% | 153.5% |
| EPS (diluted) | $3.34 | $2.28 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $661.7M | ||
| Q4 25 | $1.2B | $581.1M | ||
| Q3 25 | $1.1B | $599.7M | ||
| Q2 25 | $1.0B | $577.9M | ||
| Q1 25 | $897.8M | $544.5M | ||
| Q4 24 | $1.1B | $369.8M | ||
| Q3 24 | $1.1B | $351.5M | ||
| Q2 24 | $1.0B | $350.3M |
| Q1 26 | — | $225.8M | ||
| Q4 25 | $203.5M | $247.7M | ||
| Q3 25 | $251.4M | $246.6M | ||
| Q2 25 | $-718.5M | $215.2M | ||
| Q1 25 | $-92.5M | $89.1M | ||
| Q4 24 | $191.1M | $144.2M | ||
| Q3 24 | $215.1M | $143.2M | ||
| Q2 24 | $168.6M | $132.4M |
| Q1 26 | — | 15.1% | ||
| Q4 25 | 21.2% | 54.3% | ||
| Q3 25 | 5.1% | 53.6% | ||
| Q2 25 | -65.6% | 48.8% | ||
| Q1 25 | -6.2% | 22.3% | ||
| Q4 24 | 17.5% | 50.7% | ||
| Q3 24 | 24.7% | 53.1% | ||
| Q2 24 | 19.5% | 49.3% |
| Q1 26 | — | 34.1% | ||
| Q4 25 | 17.0% | 42.6% | ||
| Q3 25 | 22.3% | 41.1% | ||
| Q2 25 | -68.7% | 37.2% | ||
| Q1 25 | -10.3% | 16.4% | ||
| Q4 24 | 17.6% | 39.0% | ||
| Q3 24 | 20.4% | 40.7% | ||
| Q2 24 | 16.5% | 37.8% |
| Q1 26 | — | $2.28 | ||
| Q4 25 | $3.34 | $2.47 | ||
| Q3 25 | $4.08 | $2.42 | ||
| Q2 25 | $-11.74 | $2.11 | ||
| Q1 25 | $-1.52 | $0.87 | ||
| Q4 24 | $2.97 | $1.88 | ||
| Q3 24 | $3.42 | $1.86 | ||
| Q2 24 | $2.49 | $1.73 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.4B | $2.9B |
| Total DebtLower is stronger | $5.4B | — |
| Stockholders' EquityBook value | $4.3B | $9.0B |
| Total Assets | $11.7B | $68.0B |
| Debt / EquityLower = less leverage | 1.24× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $2.9B | ||
| Q4 25 | $1.4B | — | ||
| Q3 25 | $1.3B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $1.9B | — | ||
| Q4 24 | $2.4B | — | ||
| Q3 24 | $2.2B | — | ||
| Q2 24 | $1.4B | — |
| Q1 26 | — | — | ||
| Q4 25 | $5.4B | — | ||
| Q3 25 | $5.4B | — | ||
| Q2 25 | $5.4B | — | ||
| Q1 25 | $5.4B | — | ||
| Q4 24 | $6.1B | — | ||
| Q3 24 | $6.1B | — | ||
| Q2 24 | $5.7B | — |
| Q1 26 | — | $9.0B | ||
| Q4 25 | $4.3B | $9.1B | ||
| Q3 25 | $4.0B | $9.0B | ||
| Q2 25 | $3.7B | $8.8B | ||
| Q1 25 | $4.2B | $8.6B | ||
| Q4 24 | $4.1B | $5.9B | ||
| Q3 24 | $4.2B | $5.9B | ||
| Q2 24 | $3.8B | $5.7B |
| Q1 26 | — | $68.0B | ||
| Q4 25 | $11.7B | $67.2B | ||
| Q3 25 | $11.4B | $66.0B | ||
| Q2 25 | $10.9B | $65.9B | ||
| Q1 25 | $11.5B | $65.1B | ||
| Q4 24 | $12.0B | $46.4B | ||
| Q3 24 | $12.3B | $46.1B | ||
| Q2 24 | $11.4B | $45.5B |
| Q1 26 | — | — | ||
| Q4 25 | 1.24× | — | ||
| Q3 25 | 1.35× | — | ||
| Q2 25 | 1.45× | — | ||
| Q1 25 | 1.29× | — | ||
| Q4 24 | 1.49× | — | ||
| Q3 24 | 1.47× | — | ||
| Q2 24 | 1.52× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $362.5M | — |
| Free Cash FlowOCF − Capex | $345.8M | — |
| FCF MarginFCF / Revenue | 28.9% | — |
| Capex IntensityCapex / Revenue | 1.4% | — |
| Cash ConversionOCF / Net Profit | 1.78× | — |
| TTM Free Cash FlowTrailing 4 quarters | $1.3B | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $362.5M | $232.1M | ||
| Q3 25 | $474.6M | $122.4M | ||
| Q2 25 | $88.9M | $72.6M | ||
| Q1 25 | $429.8M | $-126.3M | ||
| Q4 24 | $398.6M | $354.3M | ||
| Q3 24 | $398.7M | $-246.8M | ||
| Q2 24 | $331.4M | $126.8M |
| Q1 26 | — | — | ||
| Q4 25 | $345.8M | $215.5M | ||
| Q3 25 | $459.4M | $101.7M | ||
| Q2 25 | $75.9M | $52.5M | ||
| Q1 25 | $415.9M | $-139.1M | ||
| Q4 24 | $385.3M | $340.9M | ||
| Q3 24 | $388.0M | $-254.2M | ||
| Q2 24 | $324.3M | $117.3M |
| Q1 26 | — | — | ||
| Q4 25 | 28.9% | 37.1% | ||
| Q3 25 | 40.8% | 17.0% | ||
| Q2 25 | 7.3% | 9.1% | ||
| Q1 25 | 46.3% | -25.5% | ||
| Q4 24 | 35.4% | 92.2% | ||
| Q3 24 | 36.8% | -72.3% | ||
| Q2 24 | 31.7% | 33.5% |
| Q1 26 | — | — | ||
| Q4 25 | 1.4% | 2.9% | ||
| Q3 25 | 1.3% | 3.5% | ||
| Q2 25 | 1.2% | 3.5% | ||
| Q1 25 | 1.5% | 2.4% | ||
| Q4 24 | 1.2% | 3.6% | ||
| Q3 24 | 1.0% | 2.1% | ||
| Q2 24 | 0.7% | 2.7% |
| Q1 26 | — | — | ||
| Q4 25 | 1.78× | 0.94× | ||
| Q3 25 | 1.89× | 0.50× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | -1.42× | ||
| Q4 24 | 2.09× | 2.46× | ||
| Q3 24 | 1.85× | -1.72× | ||
| Q2 24 | 1.97× | 0.96× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
JAZZ
| Xywav | $465.5M | 39% |
| Total Oncology | $337.8M | 28% |
| Rylaze Enrylaze | $108.2M | 9% |
| Zepzelca | $90.4M | 8% |
| Product And Services Royalties And Contract Revenue | $65.5M | 5% |
| High Sodium AG Oxybate Product Royalty Revenue | $55.7M | 5% |
| Xyrem | $37.8M | 3% |
| Vyxeos | $34.7M | 3% |
| Ziihera | $8.5M | 1% |
| Other Products | $2.8M | 0% |
| Sativex | $1.5M | 0% |
SSB
| Net Interest Income | $561.6M | 85% |
| Noninterest Income | $100.1M | 15% |
